Furthermore, patients received continuous capecitabine which has been shown in breast cancer to cause [18F]FLT “flare” resulting from translocation of equilibrative nucleoside transporter 1 (ENT1) to the cellular membrane and consequently an increase in [18F]FLT uptake [31, 32]. This evidence concerns the gene SLC29A1 and breast carcinoma.